Collegium Pharmaceutical reports Q3 adjusted EPS $1.61, consensus $1.59
The Fly

Collegium Pharmaceutical reports Q3 adjusted EPS $1.61, consensus $1.59

Reports Q3 revenue $159.3M, consensus $155.57M. Collegium’s strong operational execution led to record quarterly pain portfolio revenue, with 11% year-over-year growth, and enabled our recent acquisition of Ironshore, which expands our presence into neurology with the addition of Jornay PM,” said Michael Heffernan, interim President and CEO of Collegium. “We are committed to the seamless integration of Ironshore and maximizing the value of Jornay PM, which is poised to be our lead growth driver and our first step toward building another therapeutic area of focus. With the appointment of Vikram Karnani as our new CEO, Collegium is well positioned for its next phase of growth.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App